Merck buys Rigontec for up to €464mm
Executive Summary
Merck & Co. Inc. will pay €115mm ($136.9mm) up front to acquire Rigontec GMBH, a privately held biotech developing immuno-oncology therapies targeting the retinoic acid-inducible gene I (RIG-I) pathway in the innate immune system. The deal also includes up to €349mm in development, regulatory, and commercialization earn-outs.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice